Mid-Atlantic BioTherapeutics, Inc. Begins $5 Million Funding Round
Mid-Atlantic BioTherapeutics, Inc. (the "Company"), a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies and developing treatments for central nervous system ("CNS") disorders, has launched a new funding initiative. This effort aims to raise up to $5 million via common stock offerings, which will significantly assist in the acceleration of their clinical programs and expand their market presence globally.
Utilizing Funds to Propel Development Efforts
The capital raised from this funding round will be instrumental in enhancing the Company's drug development processes. It plans to allocate these funds primarily for preparing the necessary clinical trials and regulatory filings, ensuring that they meet all required compliance standards. Additionally, this financial boost will support any potential exit opportunities that may arise and cover essential corporate expenses.
CEO Comments on Funding Importance
Dr. David Horn, the CEO and Founder, expressed enthusiasm about this funding initiative, stating, "This fundraising round will provide the capital we need to advance our clinical-stage technologies and prepare for greater access to global markets. We are thrilled to invite accredited investors to participate in this significant milestone for our Company." His leadership reflects a commitment to pushing the boundaries of medical science through innovative solutions.
Details About the Offering
This funding opportunity offers investors a chance to acquire shares at a price of $5.00 each, with a minimum investment set at $50,000. Furthermore, there are additional incentives for larger investments. Those who invest between $250,000 and $500,000 will receive warrants to purchase an extra 10% of their shares, while those investing between $500,001 and $1,000,000 will receive warrants for 15% additional shares. Investors exceeding $1,000,000 will benefit from warrants for 20% additional shares.
Open Exclusively to Accredited Investors
This offering is strictly available to accredited investors, as outlined by regulatory guidelines. It is designed to be conducted in compliance with applicable exemptions from registration under federal and state securities laws, ensuring that all regulatory requirements are met.
About Mid-Atlantic BioTherapeutics, Inc.
Founded in 2011 and established at the Pennsylvania Biotechnology Center, Mid-Atlantic BioTherapeutics, Inc. has dedicated itself to creating innovative therapies that address significant health challenges posed by infectious diseases and CNS disorders. The Company is spearheaded by a proficient team of Ph.D. and M.D. professionals who bring decades of expertise in drug discovery and development to the table.
Research and Development Focus Areas
Mid-Atlantic BioTherapeutics is committed to advancing two primary technology platforms:
- IMT504: This groundbreaking immunotherapy platform is tailored to combat severe infectious diseases, including rabies. The Company is advancing preparations for pivotal clinical trials, guided by its Orphan Drug Designation.
- USP30-Targeted Therapies: In collaboration with Accelero BioStructures, the Company is developing novel inhibitors targeting USP30, focusing on conditions such as Parkinson's and Alzheimer's diseases. This partnership leverages state-of-the-art AI and machine learning technologies to hasten the discovery of promising candidates.
The Company’s innovative frameworks position it to potentially lead in global markets focused on infectious diseases and CNS therapeutics.
Frequently Asked Questions
What is the goal of Mid-Atlantic BioTherapeutics' funding round?
The aim is to raise $5 million to accelerate clinical programs and expand market reach.
Who can participate in the funding?
The offering is exclusively open to accredited investors, per regulatory standards.
What are the benefits of investing larger amounts?
Investors making larger investments can receive additional warrants for extra shares, increasing their potential returns.
What therapeutic areas does Mid-Atlantic BioTherapeutics focus on?
The Company specializes in immunotherapies for infectious diseases and treatments for central nervous system disorders.
How long has Mid-Atlantic BioTherapeutics been in operation?
The Company was founded in 2011 and has consistently pursued innovations in biotechnology.
